End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
43.3 SEK | +0.70% | +1.41% | +29.64% |
22/04 | EQL Pharma AB Announces Mellozzan Launched in Germany and Austria | CI |
13/02 | EQL Pharma AB Provides Sales Guidance for the Year 2023/24 | CI |
Sales 2024 * | 363M 33.19M 2.77B | Sales 2025 * | 425M 38.82M 3.24B | Capitalization | 1.26B 115M 9.59B |
---|---|---|---|---|---|
Net income 2024 * | 60M 5.48M 457M | Net income 2025 * | 76M 6.95M 579M | EV / Sales 2024 * | 3.58 x |
Net Debt 2024 * | 41M 3.75M 312M | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 2.96 x |
P/E ratio 2024 * |
20.9
x | P/E ratio 2025 * |
16.5
x | Employees | 19 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 100% |
1 day | +0.70% | ||
1 week | +1.41% | ||
Current month | +2.36% | ||
1 month | +5.61% | ||
3 months | +21.97% | ||
6 months | +69.80% | ||
Current year | +29.64% |
Managers | Title | Age | Since |
---|---|---|---|
Axel Schörling
CEO | Chief Executive Officer | 38 | 01/18/01 |
Founder | 59 | 01/06/01 | |
Anna Jönsson
DFI | Director of Finance/CFO | 40 | 15/21/15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 59 | 01/06/01 | |
Director/Board Member | 63 | 01/15/01 | |
Director/Board Member | 51 | 01/20/01 |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 43.3 | +0.70% | 6,415 |
25/24/25 | 43 | -0.92% | 2,142 |
24/24/24 | 43.4 | -0.23% | 4,478 |
23/24/23 | 43.5 | +2.35% | 12,185 |
22/24/22 | 42.5 | -0.47% | 9,771 |
End-of-day quote NORDIC GROWTH MARKET, April 26, 2024
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+29.64% | 115M | |
-32.21% | 15.27B | |
-31.97% | 10.84B | |
-30.42% | 6.06B | |
+8.14% | 6.04B | |
-11.41% | 5.86B | |
-0.88% | 4.71B | |
+52.19% | 4.29B | |
-12.31% | 3.61B | |
-14.86% | 3.33B |
- Stock Market
- Equities
- EQL Stock